Dexmedetomidine as a Pain Management Adjunct in the Pediatric Population Undergoing Posterior Spinal Fusion

STUDY00002630

This randomized controlled trial examines whether the addition of a low-dose dexmedetomidine infusion to our current multimodal pain management plan decreases narcotic consumption and reduces side effects in adolescent patients undergoing posterior spinal fusion for idiopathic scoliosis.

2024-07-01

2026-07-01

2026-07-01

Not yet recruiting

Early phase I

160

Inclusion Criteria: * Diagnosis of idiopathic scoliosis * Undergoing a posterior spinal fusion of at least 5 levels with both thoracic and lumbar involvement Exclusion Criteria: * Known allergy to dexmedetomidine or any of the standard medications used intra or post operatively * Patients with a history of chronic pain currently taking opioids, TCA's, Gabapentinoids * Medical contraindications to administration of dexmedetomidine, unstable cardiac status, (prolonged Qtc, life threatening arrhythmias, use of digoxin) * Moya Moya disease

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 160, 'type': 'ESTIMATED'}}

2024-06-03